NIM
ITCI

NXG Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

NXG Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,248
Closed -$756K – 92
2022
Q2 		$756K Sell
13,248
-241
-2% -$13.7K 0.08% 59
2022
Q1 		$825K Sell
13,489
-79
-0.6% -$4.1K 0.07% 64
2021
Q4 		$710K Buy
13,568
+5,928
+78% +$249K 0.07% 84
2021
Q3 		$285K Buy
7,640
+70
+0.9% +$2.43K 0.03% 106
2021
Q2 		$309K Sell
7,570
-659
-8% -$24.4K 0.03% 104
2021
Q1 		$279K Buy
8,229
+1,856
+29% +$64.4K 0.03% 102
2020
Q4 		$203K Buy
+6,373
New +$167K 0.02% 125

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NXG Investment Management's ITCI Position: Q3 2022 in Review

NXG Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2022, closing a stake of 13,248 shares — an estimated $756K sold.

NXG Investment Management first reported a position in ITCI in Q4 2020 and held it in 7 quarters. The position peaked at $825K in Q1 2022. 274 funds tracked by Wall St. Rank hold ITCI as of Q3 2022.

  • NXG Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2022 after selling out during the quarter.
  • NXG Investment Management sold 13,248 Intra-Cellular Therapies Inc. shares in Q3 2022, an estimated $756K.
  • NXG Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 7 quarters.
  • NXG Investment Management's Intra-Cellular Therapies Inc. position peaked at $825K in Q1 2022.
  • 274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2022.

Based on NXG Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.